Home/Pipeline/Undisclosed Neurology Program(s)

Undisclosed Neurology Program(s)

Neurodegenerative Diseases

PreclinicalActive

Key Facts

Indication

Neurodegenerative Diseases

Phase

Preclinical

Status

Active

Company

Base4

About Base4

Base4 Biotechnology is a private, preclinical-stage company pioneering a structure-based approach to discover small molecules that target RNA, a challenging but high-potential therapeutic modality. Its core asset is the VERITAS Platform, an AI and quantum biophysics-enhanced platform designed to resolve the dynamic atomic structures of RNA and identify druggable sites. Led by a seasoned team with prior biotech founding and exit success, the company is advancing internal programs while seeking strategic partnerships to accelerate drug development in neurodegenerative diseases, oncology, and rare conditions.

View full company profile

Therapeutic Areas

Neurology Oncology Neuromuscular Rare Diseases

Other Neurodegenerative Diseases Drugs

Drug	Company	Phase	Status
Undisclosed	Modulo Bio	Discovery	Active
PBI-01207	Phoenix Biotechnology	Pre-clinical	Active
Therapeutic Target Discovery Platform	ValtedSeq	Discovery	Active
Platform Application for Neurodegenerative Diseases	ALTUCELL	Pre-clinical/Research	Active
OGG1 Activator Program	Luciole Pharmaceuticals	Pre-clinical	Active
Lysosome Biology Program	Talisman Therapeutics	Preclinical	Active
Microglial Health Program	Talisman Therapeutics	Preclinical	Active
HSF1 Activator Program	Sisu Pharma	Pre-clinical	Active
Platform-derived candidates	VRG Therapeutics	Pre-clinical	Active
Neurodegenerative Biomarkers R&D	Firalis	Development	Active
Neurodegeneration Pipeline	Origenis	Preclinical	Active
Enhanced Brain Delivery (EBD™) Platform	Acumen Pharmaceuticals	Preclinical	Research Stage